For the estimated 21,000 patients who will receive a diagnosis of chronic lymphocytic leukemia (CLL), 20% of them will have early-stage disease. Unfortunately, that 20% will not be offered treatment, as the current management of these patients follows a “watch-and-wait” paradigm. However, with the advent of better prognostic tools to identify patients at high risk, in addition to the recent approval of several novel oral agents with impressive efficacy, re-examining this approach now seems prudent.

If you’re a specialist and dealing with patients all day, there are many things you’d likely want them to know before meeting with you. This list of a dozen things taken directly from practicing OB/GYN physicians can likely be shared across many specialties. How many of these little pieces of advice do you share with your own patients?

The short answer? No. That’s the sentiment from the 12,000+ physicians across 29 specialists who took part in Medscape’s recently released Physician Lifestyle & Happiness Report 2021. Physician burnout and dissatisfaction are not new, but before the pandemic in last year’s survey, 82% of doctors reported they were largely happy outside of work. In 2021, only 58% can say the same.

Clinical Advances in Hematology & Oncology presents a review of selected presentations from the 2020 SABCS Virtual Symposium, which took place in December 2020. Expert commentary is provided by Joyce A. O’Shaughnessy, MD of Baylor University Medical Center and the Director of the Breast Cancer Research Program, Texas Oncology, US Oncology, in Dallas.

Everything in moderation, right? Well, when it comes to watching our weight, eating the right foods in moderate quantities is key. But what are those “right” foods? How can we satiate ourselves when we’re hungry and not overeat? The answer, according to the CDC, is eating more low-energy-dense foods such as fruits, veggies, and lean proteins. Read on to find five perfect examples to kill the cravings.

Dr. David P. Carbone, Director of the Thoracic Oncology Center at Ohio State University, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases: “…the initial hope that PD‑1 inhibitors could be active on brain metastases has not been fully fulfilled, and the aggressive use of stereotactic radiation in that setting is useful.”